Ichthyosis vulgaris (IV)X-linked recessive ichthyosis (XLRI)Autosomal recessive congenital ichthyosisKeratinopathic ichthyosisOther rare formsReferencesFurther reading Ichthyosis is an inherited group of skin disorders characterized by xerosis and scaling. Other common phenotypic characteristics are hyperkeratosis, keratosis pilaris, palmar, and plantar hyperlinearity. It is also known as fish scale disease or the disorders of keratinization (DOK). Ichthyosis vulgaris. Image Credit: TANAPAT LEK.JIW/Shutterstock.com The clinical symptoms often appear at birth or within the first few years of life. The Ichthyosis Consensus Conference produced a consensus classification for ichthyosis in 2009 based on pathophysiology, clinical symptoms, and manner of inheritance. It is classified into two types according to this naming system: nonsyndromic forms (clinical symptoms limited to the skin) and syndromic forms (involvement of other organ systems). Ichthyosis Vulgaris and X-linked recessive ichthyosis are the most frequent, both caused by well-known genetic abnormalities. Depending on the severity of the ichthyosis, treatment should include hydration and lubrication, as well as keratolytic and keratinocyte differentiation modulators. Although oral retinoids are not normally required in the care of common ichthyoses, they are a staple in the systemic management of severe disease. The majority of ichthyosis treatments try to increase the skin’s barrier function. Bathing and carefully applying creams and ointments are important components of an ichthyosis patient’s daily regimen. Ichthyosis vulgaris (IV) The most prevalent form of ichthyosis is Ichthyosis Vulgaris (IV), which has an incidence of 1:250 to 1:1000. IV is also the mildest form of inherited nonsyndromic ichthyosis, with xerosis, scaling, eczema, and pruritus, and it is strongly linked to atopic symptoms. The phenotypic manifestations usually arise around an age of 2 months and improve in the summer. The extensor sides of the lower legs and the back are usually afflicted; the chest and abdomen are rarely impacted. Keratosis pilaris and palmoplantar hyperlinearity are both common IV complications. IV is caused by autosomal dominant mutations in the filaggrin gene (FLG), which is required for epidermal development and skin barrier formation. Population-specific FLG variants of IV have been found in Europeans, Asians, and Africans. Patients with IVs are more likely to develop atopic dermatitis, asthma, and allergies. This increased risk is likely due to a breakdown in barrier function, which may allow possible allergens to penetrate deeper into the epidermis. X-linked recessive ichthyosis (XLRI) XLRI is the second most frequent form of hereditary ichthyosis, with a male incidence ranging from 1:2000 to 1:6000. Clinical manifestations of XLRI are frequently indistinguishable from those of IV. Symptoms often begin in the neonatal period as generalized desquamation and xerosis, progressing to fine scaling of the trunk and extremities in infancy. Patients develop a brownish, polygonal, plate-like scale that tightly adheres to the skin over time. Mutations in the STS gene, which codes for steroid sulfatase, on the X chromosome cause XLRI. Some mild and severe XLRI phenotypes may be clinically difficult to distinguish from IV and ARCI (autosomal recessive congenital ichthyosis), respectively. Because around 90% of XLRI patients have substantial deletions, including STS and surrounding DNA, with contiguous gene loss in certain cases, fluorescence in situ hybridization (FISH) analysis is a valuable tool for detecting XLRI patients and carriers who have such deletions. Nonetheless, while FISH is useful in these circumstances, it is not useful in detecting other persons with partial deletions or point mutations. Autosomal recessive congenital ichthyosis ARCI refers to a collection of genetically and phenotypically diverse illnesses that includes harlequin ichthyosis (HI), lamellar ichthyosis (LI), and congenital ichthyosiform erythroderma (CIE). The incidence of ARCI has been estimated to be one in every 200,000 births. Loss-of-function mutations in ABCA12, which encodes an ATP-binding cassette (ABC) transporter, induce HI. ABCA12 is required for lipid transport into lamellar granules and is important in cornification and lipid barrier formation. Interestingly, while homozygous loss-of-function mutations in ABCA12 result in HI, missense mutations in ABCA12 result in milder LI/CIE symptoms. LI and CIE can be caused by mutations in one of nine genes – TGM1, NIPAL4/ICHTHYIN, ALOX12B, ALOXE3, CYP4F22, ABCA12, PNPLA1, CERS3, and LIPN16. TGM1 mutations are the most frequent and account for roughly 32% of ARCI17 heritability. A CIE baby is frequently born as a collodion baby. Erythroderma and scaling emerge after the collodion membrane is removed. The scales in CIE are often fine and white or light grey. The erythroderma in severe cases of CIE is systemic and permanent. However, erythroderma improves in childhood, especially in milder forms. Another minor form of ARCI is bathing suit ichthyosis (BSI). It is distinguished by a distinct pattern of lesions on the trunk, the most proximal sections of the upper limbs, the scalp, and the neck, but not on the central face and extremities. In South Africa, the term “bathing suit” ichthyosis was introduced to describe this peculiar phenotypic of lamellar ichthyosis. TGM1 missense mutations have been found in 20 BSI cases. Related Stories Neonates with HI have thick, armor-like scales on their skin, as well as significant ectropion (eversion of the eyelids), eclabium (eversion of the lips), and ear flattening. Some neonatal HI patients die; however, survival has improved with advances in neonatal intensive care and early treatment with systemic retinoids. Retinoids can help patients with lamellar ichthyosis, epidermolytic hyperkeratosis, or congenital ichthyosiform erythroderma because the drugs’ keratolytic properties allow shedding and prevent future hyperproliferation. It is recommended that these medications be provided in low, effective doses because their use in ichthyosis patients could be lifelong. Ichthyosis Vulgaris | Causes, Signs & Symptoms, Diagnosis, TreatmentPlay Keratinopathic ichthyosis Keratinopathic ichthyosis refers to disorders caused by gene mutations in the keratin family. Epidermolytic ichthyosis, or EI, is the most common type. Minor varieties include superficial EI (SEI), annular EI (AEI), and Curth-Macklin ichthyosis. Mutations in the keratin family genes KRT1, KRT2, and KRT10 cause all kinds of keratinopathic ichthyosis. EI is the most common keratinopathic ichthyotic phenotype, with extensive blister formation and numerous erosions with erythroderma. At birth, the patients have blistering and erythema, which fade with age, and in adulthood, they have extensive epidermolytic hyperkeratosis. Because there is so much phenotypic heterogeneity in EI,
Month: September 2023
2023 Cardiovascular Drugs Market Report: Comprehensive Insights The “Cardiovascular Drugs Market Report 2023” provides an in-depth analysis of the competitive landscape in the industry. This report sheds light on company profiles, financial metrics, market demand, innovations, and the global footprint of major players. If you’re involved in the Cardiovascular Drugs market or looking to enter, this report is your comprehensive guide. The global Cardiovascular Drugs market was valued at USD 6014.9 million in 2022 and is anticipated to reach USD 6361.2 million by 2029, witnessing a CAGR of 0.8% during the forecast period 2023-2029. Brief Description About Cardiovascular Drugs Market:- Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).HighlightsThe global Cardiovascular Drugs market was valued at USD 6014.9 million in 2022 and is anticipated to reach USD 6361.2 million by 2029, witnessing a CAGR of 0.8% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.Geographically, North America captured lions share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East and Africa.Report ScopeThis report aims to provide a comprehensive presentation of the global market for Cardiovascular Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiovascular Drugs.The Cardiovascular Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue (USD millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cardiovascular Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.Sandeep Get a Sample Copy of theCardiovascular DrugsReport 2023 Highlights of the 2023 Cardiovascular Drugs Market Report: Detailed Analysis: From company financials to product launches, get a holistic view of factors influencing the market. Regional Outlook: Understand market growth across APAC, Europe, North America, South America, and Middle East and Africa. Market Predictions: Accurate market size forecasts and trend predictions up to 2029. Competitive Analysis: Discover the strategies, market contributions, and recent developments of leading companies. This includes: Amgen AstraZeneca Bayer Bristol Myers Squibb and Pfizer Daiichi Sankyo Johnson and Johnson Merck and Co. Novartis Pfizer Portola Sanofi In Chapter 5 and Chapter 7.3, based on types, the Cardiovascular Drugs market from 2018 to 2029 is primarily split into: Renin-Angiotensin System Blockers Beta Blockers Diuretics Anti-Clotting Agents Antihyperlipidemic In Chapter 6 and Chapter 7.4, based on applications, the Cardiovascular Drugs market from 2018 to 2029 covers: Hypertension Hyperlipidemia Get a Sample PDF of report –https://www.industryresearch.biz/enquiry/request-sample/23452040 Key Insights Include: Expected CAGR during the forecast period. Analysis of factors driving Cardiovascular Drugs market growth. In-depth vendor analysis. Impact of External Factors: Understanding the influence of the COVID-19 pandemic and the Russia-Ukraine war on the Cardiovascular Drugs market. Why Choose This Report? Deep market segmentation analysis. Insights into market growth and driving factors. Detailed vendor landscape and competitive analysis. Current trends and challenges in the Cardiovascular Drugs market. For any queries, click here. [Detailed TOC of Global Cardiovascular Drugs Market Insights and Forecast to 2029] 1 Cardiovascular Drugs Market Overview 1.1 Product Overview and Scope of Cardiovascular Drugs Market 1.2 Market Segment by Type 1.2.1 Global Market Sales Volume and CAGR (%) Comparison by Type (2018-2029) 1.3 Global Market Segment by Application 1.3.1 Market Consumption (Sales Volume) Comparison by Application (2018-2029) 1.4 Global Market, Region Wise (2018-2029) 1.4.1 Global Market Size (Revenue) and CAGR (%) Comparison by Region (2018-2029) 1.4.2 United States Market Status and Prospect (2018-2029) 1.4.3 Europe Market Status and Prospect (2018-2029) 1.4.4 China Market Status and Prospect (2018-2029) 1.4.5 Japan Market Status and Prospect (2018-2029) 1.4.6 India Market Status and Prospect (2018-2029) 1.4.7 Southeast Asia Market Status and Prospect (2018-2029) 1.4.8 Latin America Market Status and Prospect (2018-2029) 1.4.9 Middle East and Africa Market Status and Prospect (2018-2029) 1.5 Global Market Size of (2018-2029) 1.5.1 Global Market Revenue Status and Outlook (2018-2029) 1.5.2 Global Market Sales Volume Status and Outlook (2018-2029) 1.6 Global Macroeconomic Analysis 1.7 The impact of the Russia-Ukraine war on the Cardiovascular Drugs Market 2 Industry Outlook 2.1 Cardiovascular Drugs Industry Technology Status and Trends 2.2 Industry Entry Barriers 2.2.1 Analysis of Financial Barriers 2.2.2 Analysis of Technical Barriers 2.2.3 Analysis of Talent Barriers 2.2.4 Analysis of Brand Barrier 2.3 Cardiovascular Drugs Market Drivers Analysis 2.4 Market Challenges Analysis 2.5 Emerging Market Trends 2.6 Consumer Preference Analysis 2.7 Industry Development Trends under COVID-19 Outbreak 2.7.1 Global COVID-19 Status Overview 2.7.2 Influence of COVID-19 Outbreak on Industry Development 3 Global Cardiovascular Drugs Market Landscape by Player 3.1 Global Cardiovascular Drugs Sales Volume and Share by Player (2018-2023) 3.2 Global Revenue and Market Share by Player (2018-2023) 3.3 Global Average Price by Player (2018-2023) 3.4 Global Gross Margin by Player (2018-2023) 3.5 Market Competitive Situation and Trends 3.5.1 Market Concentration Rate 3.5.2 Market Share of Top 3 and Top 6 Players 3.5.3 Mergers and Acquisitions, Expansion 4 Global Cardiovascular Drugs Sales Volume
Conspiracy theories are circulating online that the announcement of Jill Biden’s COVID-19 infection was “all part of the plan” to reintroduce coronavirus pandemic restrictions such as mask mandates. On Monday evening, the First Lady’s communications director Elizabeth Alexander confirmed the 72-year-old had tested positive for the virus and was experiencing “only mild symptoms.” She will remain at the family’s Delaware beach house while fighting the infection. The White House later stated that Joe Biden had tested negative, but would continue to be monitored. The president has spent much of the summer with his wife, most recently visiting Florida with her to view the destruction caused by Hurricane Idalia. A positive infection for Joe Biden, 80, would come at an inconvenient time: he is due to travel to India on Thursday for a summit of G20 leaders, before going to Vietnam for a diplomatic visit. U.S. President Joe Biden and First Lady Jill Biden walk to the White House upon arrival on the South Lawn in Washington D.C., August 26, 2023. SAUL LOEB/AFP via Getty Images However, the announcement of the First Lady’s infection comes amid a spike in infections in the U.S. spurred on by the emergence of two new variants of the virus, prompting speculation that fresh COVID restrictions could be on the horizon. In the week to August 19, there were more than 15,000 hospitalizations due to COVID-19 infections across the U.S., the most recent monitoring figures from the Centers for Disease Control and Prevention (CDC) show—a rise of nearly 19 percent on the week prior. Admissions have been steadily rising since July, but are far below the highest peaks of the pandemic and appear to be localized into hotspots. A CDC spokesperson told Newsweek on Thursday it currently has no intention to call for a return of mandated mask-wearing, but didn’t deny that this might change if cases of the new variants were to rise significantly. In August, arch conspiracy theorist Alex Jones predicted that air passengers would have to wear face masks from mid-October, before “a return to the full COVID protocol” by December. There is currently no evidence to suggest this will be the case. A Transportation Security Administration spokesperson denied the claims to the Associated Press, while a CDC spokesperson described them as “utterly false.” “HE WAS RIGHT,” Eric Spracklen, a conservative digital strategist, said on Monday evening. “Jill Biden’s positive test is all part of the plan.” “Who cares if Jill Biden has COVID?” Kandiss Taylor, a Republican candidate for Georgia governor in 2022, who has previously suggested that the portrayal of “globes” in the media was NASA “propaganda,” reacted to the news. “They are trying to push this narrative still.” One social media user wrote that the announcement of the First Lady’s positive test was “the plan to push the lockdowns through,” while another questioned why she had been infected after being vaccinated and receiving booster shots. A vaccine primarily does not stop an infection from occurring, but rather gives the body the tools to fight an infection more effectively—in the same way a castle wall does not stop an attack from happening, but rather makes the castle easier to defend when an attack occurs. Who cares if Jill Biden has COVID??? I don’t get it. They are trying to push this narrative still. Someone has a cold. Someone has the flu. Someone has allergies. Someone has diarrhea. COVID viruses have been around forever and not going away. Again, who cares! — Kandiss Taylor (@KandissTaylor) September 5, 2023 Mask wearing mandates have become a thorny political issue, pitting what some see as an infringement of their personal liberties against what health officials view as one of several measures that limit the spread of the virus among the general population. Some states have banned mask mandates in public institutions, while others have mooted a return if deemed necessary. There are differing opinions among the scientific community as to the efficacy of mask wearing, though many agree that when used in tandem with other measures—such as washing hands, social distancing and vaccination—they help stop the virus spreading. Newsweek approached the White House via email for comment on Tuesday.
BROOKLYN, NY, USA, September 5, 2023/EINPresswire.com/ — The report offers a comprehensive analysis of the leber congenital amaurosis market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market’s performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the leber congenital amaurosis market. Request for a Sample Copy of this Report: https://www.imarcgroup.com/leber-congenital-amaurosis-market/requestsample Market Overview: The 7 major Leber congenital amaurosis markets are expected to exhibit a CAGR of 3.36% during 2023-2033. The Leber congenital amaurosis market is being driven by the growing prevalence of inherited eye disorders and the increasing demand for treatments that can decelerate the progression of vision loss. Besides this, the adoption of non-invasive imaging tests, including optical coherence tomography, which provides detailed retinal images and aids in the diagnosis of retinal diseases like LCA, is further accelerating market growth. Major players in the market are investing heavily in research to understand the genetic causes of LCA and develop new therapies, resulting in a positive impact on the market. Moreover, the use of low-vision devices such as magnifiers, large print books, and electronic aids to assist individuals with LCA in maximizing their remaining vision is also contributing to market expansion. Additionally, the increasing popularity of occupational therapy and rehabilitation services among LCA patients, helping them acquire the skills and techniques necessary for everyday activities like reading and navigating their surroundings, is expected to drive the Leber congenital amaurosis market in the forecasted period. Countries Covered: • United States• Germany• France• United Kingdom• Italy• Spain• Japan Analysis Covered Across Each Country: • Historical, current, and future epidemiology scenario• Historical, current, and future performance of the leber congenital amaurosis market• Historical, current, and future performance of various therapeutic categories in the market• Sales of various drugs across the leber congenital amaurosis market• Reimbursement scenario in the market• In-market and pipeline drugs This report also provides a detailed analysis of the current leber congenital amaurosis marketed drugs and late-stage pipeline drugs. In-Market Drugs: • Drug Overview• Mechanism of Action• Regulatory Status• Clinical Trial Results• Drug Uptake and Market Performance Late-Stage Pipeline Drugs: • Drug overview• Mechanism of action• Regulatory status• Clinical trial results• Drug uptake and market performance Competitive Landscape With Key Players: The competitive landscape of the leber congenital amaurosis market has been studied in the report with the detailed profiles of the key players operating in the market. Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6909&flag=C If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization. About Us IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. Elena AndersonIMARC Services Private Limited+1 631-791-1145email us here You just read: News Provided By September 05, 2023, 09:24 GMT Share This Article EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™, tries to define some of the boundaries that are reasonable in today’s world. Please see our Editorial Guidelines for more information. Submit your press release
Share on PinterestSupplements can sometimes help people with non-alcoholic fatty liver disease. FootageStockEasy/Getty Images Researchers are reporting that resistant starch may help lower inflammation in people with non-alcoholic fatty liver disease. Legumes and whole grains are among the natural sources of resistant starch. Experts say a healthy lifestyle and healthy weight can help prevent the onset of fatty liver disease. New research indicates that resistant starch may positively affect metabolism. According to a study published today in the journal Cell Metabolism, this type of starch could also help reduce liver injury and inflammation, lowering the risk of developing non-alcoholic fatty liver disease (NAFLD). In their study, researchers recruited 200 people with NAFLD. They provided the participants with a balanced diet designed by a nutritionist. Half of the participants received a resistant starch powder derived from maize. The other half received a calorie-matched, non-resistant corn starch. The scientists instructed both groups to drink 40 grams of the starch mixed with 300 milliliters (1 ¼ cups) of water before meals twice a day for four months. After four months, researchers reported that the group that received the resistant starch treatment had almost a 40% lower liver triglyceride level compared to people in the control group. They also had reduced liver enzymes and inflammatory factors associated with NAFLD. The improvements remained when the scientists statistically adjusted for weight loss. In the second stage of this study, the researchers analyzed fecal samples from the participants. They found the resistant starch group had a different microbiota composition. The treatment group had a lower level of Bacteroides stercoris, a type of bacteria that can affect fat metabolism in the liver. The researchers transplanted fecal microbiota from the resistant starch treatment participants to mice with a high fat, high cholesterol diet. The researchers reported that there was a significant reduction in liver weight and triglyceride levels and improved liver tissue grading in the mice compared to those that received microbiota from the control group. “This study provides a very interesting mechanism on the potential role of the gut microbiome and fatty liver disease,” Dr. Hardeep Singh, a gastroenterologist with Providence St. Joseph Hospital in Orange in California who was not involved in the study, told Medical News Today. “It does provide some promising results. However, the data is very preliminary and, at this point, not something I would recommend to patients as a treatment option for fatty liver disease. Further study is required,” he added. A buildup of fat in the liver can cause NAFLD. This can lead to severe liver disease and contribute to other medical conditions, such as type 2 diabetes and cardiovascular disease. These conditions also make you more likely to develop NAFLD. “Treatment options for fatty liver disease are limited at this time,” Singh said. “Unfortunately, currently, there are no medications that have been proven to be effective for this condition. Weight loss via diet and lifestyle modification is the mainstay of therapy.” “A study showed that weight loss for morbidly obese patients via bariatric surgery can reduce fatty liver disease and scarring in the liver,” Singh added. “Multiple studies, such as this one and this one, have confirmed that 2 to 3 cups of coffee per day is effective at reducing fat and scarring in the liver in patients with fatty liver disease. We do advocate for coffee intake in patients who can tolerate 2 to 3 cups of coffee per day. The coffee has to be regular black coffee and not decaf. A few studies have documented improvement in fatty liver disease using vitamin E 800 units per day. This can be considered in select patients.” NAFLD is an accumulation of fats in the liver. Sometimes, these cause injury, inflammation, or fibrosis. These effects can sometimes be avoided by maintaining a healthy lifestyle, according to the Ohio State University, Wexner Medical Center. Following the Mediterranean diet could help, as well as monitoring your intake of simple sugars. “In some specific situations, fatty liver disease may be prevented,” Singh said. “What I mean by this is if you are obese or overweight, that will lead to insulin resistance and eventual metabolic syndrome. That is a precursor to fatty liver disease. In some patients, this can be modified and altered with lifestyle modification. Therefore, if those patients become more active and lose weight, their insulin resistance can be reduced, and they may not develop fatty liver disease.” “However, in another subset of patients with more aggressive genetics, I don’t believe fatty liver disease can be prevented,” he added. “For example, just as we have skinny patients who develop diabetes, there are a subset of patients with fatty liver disease who have a normal body mass index and no risk factors for metabolic syndrome. In those patients, the condition cannot be prevented as it appears they have a genetic predisposition.” “Resistant starch is a type of carbohydrate that acts more as a fiber than a starch,” according to Caroline Thomason, RD, CDCES, a dietitian based in Washington, D.C., who was not involved in the study. “It is digested slowly and has positive health applications for diabetes, heart disease, and digestive health.” “Anywhere between 20 grams to 50 grams of resistant starch has been studied in the research with the few side effects,” Thomason told Medical News Today. “Too much resistant starch may cause some gas and bloating in sensitive folks.” “Foods with resistant starch are often cooked – then – cooled carbohydrates,” she added. “This means if you cook white rice, let it cool in the fridge, and reheat it later as part of a meal, you will benefit from resistant starch. You may find that your blood sugar doesn’t rise quickly, and you feel fall longer, in addition to any other potential health benefits of resistant starch.” There isn’t a recommended daily allowance for resistant starches. Experts note that it is healthy to get fiber from a wide range of sources so that you have soluble, insoluble, and resistant starches every day.
Q: It looks like I have fungus beneath my toenail, but how can I be sure? Does toenail fungus go away on its own? Yellowing, brittle and unusual-looking toenails can be a sign that a fungal nail infection, called onychomycosis, has taken root. Experts say these infections don’t go away on their own and can easily spread from person to person without treatment. “Fungus tends to be greedy,” said Dr. Boni Elewski, chair of the department of dermatology at the University of Alabama at Birmingham. If you pick it up from close contact with someone who is infected or by walking barefoot in a locker room, for instance, it can then crawl under your toenail and spread into the nail itself, she said. Wearing moist, sweaty shoes can encourage the fungus to grow. Toenail fungus affects an estimated one in 10 people worldwide, and becomes more common with age — afflicting more than half of those ages 70 and up. People with diabetes or weakened immune systems are also susceptible, said Dr. Shari Lipner, a dermatologist at Weill Cornell Medical Center in New York City. Is it really fungus? Experts say the first step to getting your normal toenail back is confirming you have fungus in the first place. Some telltale signs include thickened, discolored, cracked, misshapen and occasionally painful or smelly nails. But fungus is to blame for only about half of abnormal-looking toenails, Dr. Elewski said. Toenail trauma, whether from one-time injuries or repetitive activity in too-tight shoes, can also cause discolored or thick toenails. “Eyeballs alone are not enough to be sure it’s onychomycosis,” she said. According to Dr. Lipner, doctors usually confirm toenail fungus by examining a clipping under a microscope. They can also perform a PCR test or a fungal culture to determine which fungus species infected your nail. But these tests are not always necessary because most people have a type of fungus called trichophyton rubrum, Dr. Lipner said. If your treatment isn’t working, however, your dermatologist may want to learn more about the organism living under your nail. Prescription antifungals usually take care of the problem, but it’s a bad idea to take them without confirming you have the fungus first, Dr. Elewski said. Unnecessary antifungal use can make these drugs less effective over time, contributing to a growing problem called antifungal resistance. Which antifungals work best? Although some drugstores devote entire aisles to over-the-counter fungus salves, Dr. Elewski said that the best a nonprescription treatment or home remedy can do is improve your nail appearance. If you want to actually kill the fungus, “a prescription antifungal is the only option,” said Dr. Antonella Tosti, a dermatologist who treats nail disorders at the University of Miami Miller School of Medicine. There are topical prescriptions, including creams, ointments or serum-like solutions; and oral antifungals, meaning pills. Topical antifungals can be useful for milder cases affecting just one or two toenails, Dr. Lipner said. But one downside is that you might have to apply the medication for about a year before the fungus is completely gone. If there’s fungus under multiple nails, or if the toenails are extra thick, Dr. Lipner said, she usually opts for oral prescriptions. These pills, terbinafine or itraconazole, can kill toenail fungus in about three months. Even after the oral pills kill off the fungus, though, Dr. Lipner said that your toenail may look funky for a year as the new, uninfected toenail grows in. In the meantime, some drugstore remedies could improve nail appearance by soothing the surrounding skin or thinning the nail, Dr. Elewski said. It’s also usually fine to use nail polish on your infected toenail while taking oral antifungals, Dr. Lipner said. But don’t do that if you’re using topical medications. Whether you’re prescribed a topical or oral antifungal, Dr. Tosti said it’s important to stay on top of the treatment every day. “This is not something you can cure in a few weeks,” she said. “Compliance is very important.” Avoiding repeat infections Successfully eliminating toenail fungus doesn’t mean you can’t get it again, experts warn. In fact, an estimated 25 percent of people get repeat infections. Dr. Lipner recommended thoroughly washing any socks or other clothing that was in contact with your first infection, and discarding or using disinfectant spray on shoes you wore often when you had toenail fungus. To stave off toenail fungus in general, keep your toenails trimmed and avoid walking around barefoot in gym locker rooms or around swimming pools, Dr. Lipner said. If you sweat often in closed-toed shoes, wear moisture-wicking socks and change into dry shoes if you can. If the skin on your foot becomes dry, itchy, flaky or inflamed, you might have athlete’s foot, which is caused by the same fungus that can spread to your toenail. So it’s important to get treated right away. Unlike with toenail fungus, some over-the-counter medications can help with athlete’s foot. “But don’t go blindly treating yourself,” Dr. Lipner said. “You want to confirm with a dermatologist you’re treating the right thing.” Caroline Hopkins is a health and science journalist based in Brooklyn.
The Finnish parliament’s restaurants have stopped serving Pepsi over the soft drink’s parent company continuing its operations in Russia. PepsiCo products are no longer available on the parliament’s premises, Finland’s public broadcaster Yle reported Tuesday The decision follows a complaint from centrist member of parliament, Tuomas Kettunen, who on Monday asked the parliament to “set an example” by stopping the sale of “blood Pepsi.” Last week, PepsiCo was added to the list of private companies that Ukraine considers to be “war sponsors” of Russia’s aggression in Ukraine. The company stopped producing Pepsi, Mountain Dew and 7UP in Russia last September, but continues to sell its products in the country, where its profits quadrupled last year. PepsiCo was not immediately available for comment.
Cardiovascular Information System Market with analysis of such parameters i.e. industry growth drivers, supply and demand, risks, market attractiveness, annual growth comparison, BPS analysis, SWOT analysis and Porter’s Five Forces model. Cardiovascular Information System Market report gives inside and out audit of the Expansion Drivers, Potential Challenges, Distinctive Trends, and Opportunities for Market Players. Our Research experts have carried out detailed checks of the critical environment and have predicted the methodological structure used by market participants. The primary goal of the Cardiovascular Information System business report is to supply key insights on competition positioning, current scope, market potential, growth rates, and alternative relevant statistics. List of Top Key Players in Cardiovascular Information System Market Report Are: The survey describes the qualities of the entire company based on industry-wide analysis. Lumedx Merge Healthcare Cerner Corporation GE Healthcare Fujifilm Medical Systems McKesson Corporation Digisonics Philips Healthcare Agfa Healthcare Siemens Healthcare Get a Sample PDF of report @ https://www.360marketupdates.com/enquiry/request-sample/20949543 Cardiovascular Information System Market Report Contains 2023: – Complete overview of the global Cardiovascular Information System Market Top Country data and analysis for United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Cardiovascular Information System Markets such as North America, Europe, Asia-Pacific, South America and Middle East and Africa Description and analysis of Cardiovascular Information System market potential by type, Deep Dive, disruption, application capacity, end use industry impact evaluation of most important drivers and restraints, and dynamics of the global Cardiovascular Information System Market and current trends in the enterprise Cardiovascular Information System Market Summary: Cardiovascular Information System Marketsize, segment (mainly coveringMajorType (, Web-based, Onsite, ,),End Users (, Catheterization, ECG, Holter, ICD, Electrocardiography,), and regions), recent status, development trendsa and competitor landscape. Furthermore, the 123 pages report provides detailed cost analysis, supply chain. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream end users. Also, Consumer behaviour analysis and market dynamics (drivers, restraints, opportunities) provides crucial information for knowing the Cardiovascular Information System market. Ask For A Sample Copy of the Report Global Cardiovascular Information System Market: Market Segmentation Analysis The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments. Based on Product Type, this report shows the creation, income, cost, piece of the pie, and development pace of each kind, principally split into: Web-based Onsite On the Basis of the End-User/Applications, this report focuses on the status and outlook for major applications production, revenue, price, market share, and growth rate: Catheterization ECG Holter ICD Electrocardiography Enquire before purchasing this report – https://www.360marketupdates.com/enquiry/pre-order-enquiry/20949543 Key Benefits of This Market Research: Industry drivers, restraints, and opportunities covered in the study Neutral perspective on the market performance Recent industry trends and developments Competitive landscape and strategies of key players Potential and niche segments and regions exhibiting promising growth covered Historical, current, and projected market size, in terms of value In-depth analysis of the Cardiovascular Information System Market Overview of the regional outlook of the Cardiovascular Information System Market Valuable Points from Cardiovascular Information System Market Research Report 2022-2028: Significant changes in Market dynamics. Reporting and assessment of recent industry developments. A complete background analysis, which includes a valuation of the parental Cardiovascular Information System Market. Current, Historical, and projected size of the Cardiovascular Information System Market from the viewpoint of both value and volume. Cardiovascular Information System Market segmentation according to Top Regions. Cardiovascular Information System Market shares and strategies of key Manufacturers. Emerging Specific segments and regional for Cardiovascular Information System Market. An objective valuation of the trajectory of the Market. Recommendations to Top Companies for reinforcement of their foothold in the market. Cardiovascular Information System Market Report Gives Answers to Following Key Questions: What will the growth rate of the Cardiovascular Information System market be? What is the analysis of the sales volume, sales and prices of the leading manufacturers in the Cardiovascular Information System market? What are the key drivers of the Global Cardiovascular Information System Market? Who are the major players in the Cardiovascular Information System market? Who are the key market players in the Cardiovascular Information System Market? Which Market opportunities, risks and business strategies adopted by them? What are the Cardiovascular Information System market opportunities and threats facing suppliers in the global Cardiovascular Information System Industry? What is the regional sales, revenue and price analysis of the Cardiovascular Information System industry? Who are the distributors, traders and resellers in the Cardiovascular Information System market? Which are the major regions for dissimilar trades that are expected to eyewitness astonishing growth for the Cardiovascular Information System Market? What are the regional growth trends and the leading revenue-generating regions for the Cardiovascular Information System Market? Request for a Sample PDF of Report: https://www.360marketupdates.com/enquiry/request-sample/20949543 Key Reasons to Buy this Report: Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analysed to tell you why your market is set to change This enables you to anticipate market changes to remain ahead of your competitors You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly Provision of market value (USD Billion) data for each segment and sub-segment Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are
What is POEMS syndrome?SymptomsPolyneuropathyOrganomegalyEndocrinopathy/edemaMonoclonal gammopathySkin changesOther symptomsPathophysiologyDiagnosisTreatmentReferences Further reading ‘POEMS syndrome’ refers to polyneuropathy, organomegaly, endocrinopathy/edema, monoclonal gammopathy, and skin changes. Taken together, these symptoms reflect a paraneoplastic disease that, in rare cases, arises in patients with plasma cell neoplasms. Image Credit: Bangkok Click Studio/Shutterstock.com What is POEMS syndrome? A plasma cell neoplasia is a benign or malignant disease defined by the overproduction of plasma cells. The three types of plasma cell neoplasms include monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma, and multiple myeloma. POEMS syndrome can develop in patients aged 50 or older in extremely rare cases of plasma neoplastic diseases. Notably, men are at a 1.5 times greater risk of POEMS syndrome than women. Due to the rarity of POEMS syndrome, it is often difficult to recognize. As a result, the incidence of this paraneoplastic syndrome is likely underrepresented, leading to challenges in its management. Symptoms As indicated in its name, POEMS syndrome is associated with several distinct signs and symptoms. Polyneuropathy Polyneuropathy can cause patients with POEMS syndrome to experience numbness, tingling, and/or weakness in their extremities, particularly in the legs and hands. Patients may also feel burning, tickling, numbness, and/or prickling sensations in the skin. Polyneuropathy may also cause the patient to experience difficulty breathing. Organomegaly POEMS syndrome often leads to spleen, liver, and/or lymph node enlargement. Endocrinopathy/edema Endocrinopathy occurs when the endocrine glands produce insufficient or excessive levels of their respective hormones. Thus, this symptom of POEMS syndrome depends on the affected gland/hormone. Some potential manifestations of endocrinopathy may include hypogonadism, diabetes mellitus, hypothyroidism, and primary adrenal insufficiency. Gynecomastia or impotence may develop among men, whereas women may experience amenorrhea, enlarged breasts, abnormal lactation, and/or galactorrhea. The ‘E’ in POEMS syndrome can also refer to edematous tissues. This may arise due to increased fluid in the arms and legs, pericardium, peritoneal cavity, or behind the optic nerve. Monoclonal gammopathy Monoclonal gammopathy is the presence of excessive monoclonal (M) proteins in the blood due to the circulation of abnormal plasma cells. In addition to high M protein levels, monoclonal gammopathy may cause plasmacytomas and/or osteosclerosis. Skin changes Several dermatological symptoms are associated with POEMS syndrome, including hyperpigmentation, excessive hair growth, scleroderma, excessive sweating, and clubbed fingernails. Blue discoloration of extremities, white discoloration of the nails, as well as fat wasting at the temples, may also occur in POEMS syndrome. Other symptoms In addition to the hallmark symptoms of POEMS syndrome, several other systemic manifestations of this disorder have been described. Within the blood, for example, POEMS syndrome may lead to thrombocytosis, arterial and/or venous thrombosis, pulmonary arterial hypertension, and increased red blood cell (RBC) counts. Aside from its presence due to polyneuropathy, difficulty breathing may also be caused by fluid within the lungs, respiratory insufficiency, or reduced total lung capacity. Patients with POEMS syndrome may also present with headaches, nausea, weight loss, and fatigue. What is POEMS?Play Pathophysiology Although the exact cause of POEMS syndrome remains unknown, several mechanisms are believed to contribute to the pathophysiology of this disorder. Vascular endothelial growth factor (VEGF), produced by malignant plasma cells, is often present at increased levels in POEMS patients. Elevated VEGF levels can increase the permeability of vascular tissues, as well as lead to angiogenesis and the growth of endothelial cells. Aside from VEGF, other pro-inflammatory cytokines have been implicated in POEMS syndrome, the most notable of which include interleukin 1β (IL-1β), IL-6, and tumor necrosis factor α (TNF-α). These cytokines are often produced at high levels in POEMS syndrome, subsequently increasing inflammation. Diagnosis Both polyneuropathy and monoclonal gammopathy must be present for a POEMS diagnosis. Suspected POEMS syndrome cases should undergo a thorough clinical evaluation consisting of a physical exam, medical history, and laboratory testing. Furthermore, the treating clinician should examine the patient’s eyes, skin, neurological status, and overall organ function. Increased levels of M-proteins, blood plasma, VEGF, and the aforementioned pro-inflammatory cytokines within the serum may be used to support a POEMS syndrome diagnosis. Radiographic imaging may also detect osteosclerotic lesions. Treatment Typically, the treatment for POEMS syndrome is symptomatic. For example, patients with localized osteosclerotic lesions may benefit from radiation treatment and/or surgical removal of the lesion. Conversely, widespread osteosclerotic lesions may be managed with certain antineoplastic agents to improve associated symptoms in these patients. In addition to managing extensive osteosclerosis, chemotherapy may eliminate excessive M proteins circulating in the blood of POEMS syndrome patients. References Faizan, U., Sana, M. K., Farooqi, M. S., & Hasmi, H. (2022). Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome – A Systematic Review. Clinical Lymphoma Myeloma and Leukemia 22(2); e26-e33. doi:10.1016/j.clml.2021.07.033. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) – Patient Version [Online]. Available from: https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq. POEMS syndrome [Online]. Available from: https://www.mayoclinic.org/diseases-conditions/poems-syndrome/symptoms-causes/syc-20352678. POEMS Syndrome [Online]. Available from: https://rarediseases.org/rare-diseases/poems-syndrome/. Jurczyszyn, A., Castillo, J. J., Olszewska-Szopa, M., et al. (2022). POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy – 108 Patients Multicenter Analysis. Clinical Lymphoma Myeloma and Leukemia 22(5); 297-304. doi:10.1016/j.clml.2021.10.007. Further reading
The Florida Department of Health is reporting an uptick in COVID cases this summer. In the week prior to Aug. 19, the U.S. saw 15,067 COVID hospital admissions, an 18.8% increase over the previous week, with a slight rise in deaths, according to the Centers for Disease Control and Prevention. University of South Florida professor Jill Roberts said while COVID rates had plateaued with the COVID variant, Omicron, a new variant called Eris has contributed to the increased infections. Eris has become a dominant variant in the U.S., accounting for 21.5% of COVID infections between Aug. 20 and Sept. 2, according to the CDC. Between Aug. 11 and Aug. 17, Manatee County had 254 COVID cases, and Sarasota County had 305 reported cases, according to the Florida Department of Health. Who are the Grenons?Bradenton family on trial, charged with selling bleach as COVID cure What’s causing the surge? Roberts said the uptick can be credited to the combination of a new variant, kids returning to school, and waning immunity, which is developed by either being vaccinated or developing antibodies after a COVID infection. More on COVID:Sarasota Memorial Hospital workers receive death threats after COVID-19 response report She has anecdotally seen more people wear masks, but she said people have grown complacent with protecting themselves and others from COVID. “We have to keep in mind that COVID is a severe disease for some individuals,” Roberts said. “We don’t necessarily know our own health status, and a lot of us may underestimate our own risk.” When will COVID finally go away? COVID may never go away until a vaccine is developed to fully stop transmission of the infection, Roberts said. The transmission of COVID allows it to mutate, creating variants that can cause these surges of infections. “It’s incredibly annoying to have to deal with wave after wave of this disease without it going away,” Roberts said. “Preventing death and hospitalizations is great, but we need to get a better vaccine to stop this disease. Without serious advancement in the science, this is going to continue.” How to best stay protected from the virus? Roberts recommends testing for COVID if you’re symptomatic. The most common symptoms associated with the infection include fever, cough, new loss of smell or taste, congestion, and nausea, according to the CDC. If sick, try to stay home and away from others, and if going out, make sure to wear a mask to not expose anyone else. Additionally, there is going to be a booster shot that will be released in September. Updated vaccination can prevent or mitigate the effects of COVID, but Roberts added that someone should wait a few months to get the booster if they recently had COVID to ensure their receiving as many antibodies against the disease as possible.